These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39388374)

  • 1. Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader.
    Zhou L; Zhou K; Chang Y; Yang J; Fan B; Su Y; Li Z; Mannan R; Mahapatra S; Ding M; Zhou F; Huang W; Ren X; Xu J; Wang GX; Zhang J; Wang Z; Chinnaiyan AM; Ding K
    J Med Chem; 2024 Oct; 67(20):18247-18264. PubMed ID: 39388374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.
    Yang J; Chang Y; Tien JC; Wang Z; Zhou Y; Zhang P; Huang W; Vo J; Apel IJ; Wang C; Zeng VZ; Cheng Y; Li S; Wang GX; Chinnaiyan AM; Ding K
    J Med Chem; 2022 Aug; 65(16):11066-11083. PubMed ID: 35938508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition.
    Chang Y; Wang X; Yang J; Tien JC; Mannan R; Cruz G; Zhang Y; Vo JN; Magnuson B; Mahapatra S; Cho H; Dhanasekaran SM; Wang C; Wang Z; Zhou L; Zhou K; Zhou Y; Zhang P; Huang W; Xiao L; Liu WR; Hamadeh R; Su F; Wang R; Miner SJ; Cao X; Cheng Y; Mehra R; Ding K; Chinnaiyan AM
    Cell Rep Med; 2024 Oct; 5(10):101752. PubMed ID: 39353441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
    Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
    Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9.
    Wang C; Wang M; Wang Y; Rej RK; Aguilar A; Xu T; Bai L; Tošović J; McEachern D; Li Q; Sarkari F; Wen B; Sun D; Wang S
    J Med Chem; 2024 Aug; 67(16):14125-14154. PubMed ID: 39132814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a Potent, selective and orally bioavailable CDK9 degrader for targeting transcription regulation in Triple-Negative breast cancer.
    Nie HJ; Li BF; Sun J; Yuan Y; Zhang ZG; Hu H; Wang WJ; Chen Z; Wang S; Huang W; Diao X; Yu J; Huang R; Chen XH
    Bioorg Chem; 2024 Dec; 153():107876. PubMed ID: 39406109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Orally Bioavailable and Potent CDK9 Inhibitors for Targeting Transcription Regulation in Triple-Negative Breast Cancer.
    Wang WJ; Gao L; Wang S; Huang W; Meng XY; Hu H; Chen Z; Sun J; Yuan Y; Zhou Y; Diao X; Huang R; Li J; Chen XH
    J Med Chem; 2024 Jun; 67(12):10035-10056. PubMed ID: 38885173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.
    Han X; Zhao L; Xiang W; Qin C; Miao B; McEachern D; Wang Y; Metwally H; Wang L; Matvekas A; Wen B; Sun D; Wang S
    J Med Chem; 2021 Sep; 64(17):12831-12854. PubMed ID: 34431670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
    Quereda V; Bayle S; Vena F; Frydman SM; Monastyrskyi A; Roush WR; Duckett DR
    Cancer Cell; 2019 Nov; 36(5):545-558.e7. PubMed ID: 31668947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo.
    Wei M; Zhao R; Cao Y; Wei Y; Li M; Dong Z; Liu Y; Ruan H; Li Y; Cao S; Tang Z; Zhou Y; Song W; Wang Y; Wang J; Yang G; Yang C
    Eur J Med Chem; 2021 Jan; 209():112903. PubMed ID: 33256948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a Novel Orally Bioavailable FLT3-PROTAC Degrader for Efficient Treatment of Acute Myeloid Leukemia and Overcoming Resistance of FLT3 Inhibitors.
    Wang J; Rong Q; Ye L; Fang B; Zhao Y; Sun Y; Zhou H; Wang D; He J; Cui Z; Zhang Q; Kang D; Hu L
    J Med Chem; 2024 May; 67(9):7197-7223. PubMed ID: 38655686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies.
    Yu X; Xu J; Shen Y; Cahuzac KM; Park KS; Dale B; Liu J; Parsons RE; Jin J
    J Med Chem; 2022 Feb; 65(4):3644-3666. PubMed ID: 35119851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective Degradation of MLK3 by a Novel CEP1347-VHL-02 PROTAC Compound Limits the Oncogenic Potential of TNBC.
    Karpińska K; Mehlich D; Sabbasani VR; Łomiak M; Torres-Ayuso P; Wróbel K; Truong VN; Serwa R; Swenson RE; Brognard J; Marusiak AA
    J Med Chem; 2024 Sep; 67(17):15012-15028. PubMed ID: 39207123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
    Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
    Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.
    Zhou H; Bai L; Xu R; Zhao Y; Chen J; McEachern D; Chinnaswamy K; Wen B; Dai L; Kumar P; Yang CY; Liu Z; Wang M; Liu L; Meagher JL; Yi H; Sun D; Stuckey JA; Wang S
    J Med Chem; 2019 Dec; 62(24):11280-11300. PubMed ID: 31747516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of orally bioavailable ALK PROTACs based ceritinib against ALK positive cancers.
    Zhou H; Hu M; Jie H; Li Y; Tang K; Pan L; Liu C; Liu Z; Chen W; Chen Y; Luo Y; Gong Y; Xie Y
    Eur J Med Chem; 2024 Dec; 279():116827. PubMed ID: 39288596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
    Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
    Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer.
    Zhang L; Zhen Y; Feng L; Li Z; Lu Y; Wang G; Ouyang L
    Eur J Med Chem; 2023 Nov; 259():115648. PubMed ID: 37478560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a first-in-class protein degrader for the c-ros oncogene 1 (ROS1).
    Yang J; Wu Y; Zhu Q; Qu X; Ou H; Liu H; Wei Y; Ge D; Lu C; Jiang B; Song X
    Bioorg Chem; 2024 Sep; 150():107590. PubMed ID: 38955003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Novel PROTAC SIRT6 Degraders with Potent Efficacy against Hepatocellular Carcinoma.
    Huang J; Su J; Wang H; Chen J; Tian Y; Zhang J; Feng T; Di L; Lu X; Sheng H; Zhu Q; Chen X; Wang J; He X; Yerkinkazhina Y; Xie Z; Shu Y; Kang T; Tang H; Qian J; Zhu WG
    J Med Chem; 2024 Oct; 67(19):17319-17349. PubMed ID: 39323022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.